Teduglutide for the Treatment of Short Bowel Syndrome
- 1 June 2006
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (6) , 1105-1109
Abstract
Objective: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS). Data Sources: Clinical literature, including both primary sources and review articles, was accessed through a search of the MEDLINE databases (1980–March 2006). Key search terms included teduglutide, ALX-0600, glucagon-like peptide-2, short bowel syndrome, short gut, and intestinal adaptation. Clinical trial and drug data were supplied by the manufacturer, NPS Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to GLP-2 and its analog, teduglutide, were analyzed. An evaluation of the research exploring teduglutide for the management of SBS was conducted. Relevant information was then selected. Data Synthesis: Research has revealed that administration of GLP-2 to patients following major small bowel resection improves intestinal adaptation and nutrient absorption. Teduglutide is an enzyme-resistant GLP-2 analog that shows promise in preventing intestinal injury, restoring mucosal integrity, and enhancing intestinal absorptive function. Conclusions: Data from ongoing clinical trials indicate that teduglutide may have the ability to enhance intestinal absorptive capacity in patients with SBS. Further studies and the completion of Phase III trials are necessary to determine the appropriate dosage and length of treatment for patients with SBS to gain optimal therapeutic benefit from this drug.Keywords
This publication has 31 references indexed in Scilit:
- The Glucagon-like Peptide-2 Receptor Mediates Direct Inhibition of Cellular Apoptosis via a cAMP-dependent Protein Kinase-independent PathwayJournal of Biological Chemistry, 2000
- Structural Determinants for Activity of Glucagon-like Peptide-2Biochemistry, 2000
- An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjectsGastroenterology, 2000
- Glucagon-Like Peptide-2 Inhibits Centrally Induced Antral Motility in PigsScandinavian Journal of Gastroenterology, 1998
- Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IVNature Biotechnology, 1997
- Outcome and intestinal adaptation in neonatal short-bowel syndromeJournal of Pediatric Surgery, 1992
- Length of residual small bowel after partial resection: Correlation between radiographic and surgical measurementsGastrointestinal Radiology, 1991
- Intestinal adaptation following jejuno-ileal bypassClinical Nutrition, 1991
- Renal catabolism of human glucagon-like peptides 1 and 2Canadian Journal of Physiology and Pharmacology, 1990
- Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive functionGut, 1971